Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose subcutaneous pasireotide for acute episodic and chronic cluster headache
2015-004436-34Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cluster Headache (CH) comparing Pasireotide single-dose arm with Placebo single-dose arm (2 arms). Primary endpoint: Headache response at 30 minutes post dose. Started Jul 2016; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2015-004436-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004436-34.